Edition:
United Kingdom

Juniper Pharmaceuticals Inc (JNP.OQ)

JNP.OQ on NASDAQ Stock Exchange Global Select Market

8.65USD
23 Apr 2018
Change (% chg)

$-0.40 (-4.42%)
Prev Close
$9.05
Open
$8.90
Day's High
$8.95
Day's Low
$8.65
Volume
11,685
Avg. Vol
18,586
52-wk High
$13.10
52-wk Low
$3.90

Chart for

About

Juniper Pharmaceuticals, Inc. is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized... (more)

Overall

Beta: 0.47
Market Cap(Mil.): $99.33
Shares Outstanding(Mil.): 10.98
Dividend: --
Yield (%): --

Financials

  JNP.OQ Industry Sector
P/E (TTM): 4.60 30.21 32.78
EPS (TTM): 1.88 -- --
ROI: 45.60 13.61 13.21
ROE: 50.16 15.28 15.01

BRIEF-Juniper Pharmaceuticals Appoints Richard Messina To Board Of Directors

* JUNIPER PHARMACEUTICALS APPOINTS RICHARD MESSINA TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

21 Mar 2018

BRIEF-Juniper Pharmaceuticals Qtrly Basic EPS $0.11

* JUNIPER PHARMACEUTICALS REPORTS FULL-YEAR 2017 FINANCIAL AND OPERATING RESULTS

08 Mar 2018

BRIEF-Juniper Pharmaceuticals To Explore Strategic Alternatives

* JUNIPER PHARMACEUTICALS - ‍ ENGAGED ROTHSCHILD AS ITS INDEPENDENT FINANCIAL ADVISOR TO ASSIST JUNIPER IN EVALUATING POTENTIAL STRATEGIC ALTERNATIVES​ Source text for Eikon: Further company coverage:

31 Jan 2018

BRIEF-Juniper Pharmaceuticals Outlines Strategic Priorities For 2018 And Reports Recent Portfolio Progress

* JUNIPER PHARMACEUTICALS OUTLINES STRATEGIC PRIORITIES FOR 2018 AND REPORTS RECENT PORTFOLIO PROGRESS

02 Jan 2018

BRIEF-Juniper Pharmaceuticals reports third quarter results

* Juniper Pharmaceuticals reports third quarter 2017 financial and operating results

02 Nov 2017

Competitors

Earnings vs. Estimates